Buy MOTS-c 10mg

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino acid mitochondria-derived peptide (MDP) encoded by a small open reading frame within the mitochondrial 12S ribosomal RNA gene — a discovery that fundamentally expanded understanding of mitochondrial biology beyond energy production to include endocrine signaling. Unlike nuclear-encoded peptides, MOTS-c is transcribed from mitochondrial DNA and translated using mitochondrial ribosomes, then exported to the cytoplasm and nucleus where it exerts transcriptional regulatory effects. Its circulating levels in blood decline significantly with age and in states of metabolic dysfunction such as obesity and type 2 diabetes, establishing it as a measurable biomarker of mitochondrial health. The primary signaling mechanism of MOTS-c involves activation of AMP-activated protein kinase (AMPK), the master cellular energy sensor that responds to elevated AMP/ATP ratios to activate catabolic pathways and suppress anabolic ones. MOTS-c activates AMPK through the AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) pathway: it inhibits the folate cycle enzyme AICAR transformylase, causing intracellular AICAR accumulation, which directly activates AMPK. AMPK activation in turn triggers mitochondrial biogenesis via PGC-1α, enhances fatty acid oxidation, improves glucose uptake via GLUT4 translocation independent of insulin, and suppresses hepatic glucose production. This makes MOTS-c a potent insulin-sensitizing agent whose mechanism of action is entirely distinct from insulin itself. In addition to its metabolic effects, MOTS-c enters the nucleus in response to metabolic and oxidative stress, where it binds to ARE (antioxidant response element) sequences and activates the NRF2-KEAP1 antioxidant pathway. This transcriptional program upregulates a suite of detoxifying enzymes including heme oxygenase-1 (HO-1), glutathione S-transferase, and thioredoxin reductase, providing robust protection against reactive oxygen species generated during exercise or metabolic challenge. The dual cytoplasmic/nuclear activity of MOTS-c — metabolic reprogramming in the cytoplasm, antioxidant gene induction in the nucleus — makes it unusual among peptide hormones in having both rapid non-genomic and slower genomic components to its action. MOTS-c levels are physiologically regulated by exercise and caloric restriction — two of the most well-validated interventions for extending healthspan. Intense aerobic exercise dramatically increases circulating MOTS-c within minutes, peaking 30–60 minutes post-exercise. This exercise-induced MOTS-c release may mediate a significant portion of the systemic metabolic benefits of physical activity, including improved insulin sensitivity, enhanced skeletal muscle oxidative capacity, and anti-inflammatory effects. The peptide thus functions as an "exercise mimetic" in the sense that exogenous administration can recapitulate key molecular downstream effects of exercise in states where physical capacity is limited by age or disease.

MOTS-c is a 16-residue peptide with a straightforward linear structure, making synthesis accessible to quality peptide manufacturers. The primary quality concern is purity: HPLC purity ≥98% with mass spectrometry confirmation of the correct molecular weight (MW 2174.5 g/mol) are the minimum acceptable standards. Endotoxin testing is particularly important for a peptide intended for injection, as bacterial lipopolysaccharide contamination from synthesis media can cause local inflammatory reactions disproportionate to the peptide's actual pharmacological activity. Research protocols derived from animal dose translation and community reporting have used MOTS-c in the range of 5–10 mg per session subcutaneously, administered 2–3 times per week. The original Lee et al. mouse studies used 0.5 mg/kg/day subcutaneously; allometric scaling to a 75 kg human gives approximately 3–5 mg per dose. Cycle lengths of 4–8 weeks with 2–4 week breaks are commonly reported, allowing assessment of metabolic response between cycles. MOTS-c is best used in the context of an active exercise program, as exercise synergizes with and may enhance its AMPK-activating effects. Storage follows standard peptide protocols: lyophilized powder at −20 °C, protected from freeze-thaw cycling. Reconstitute with bacteriostatic water (not saline, which can degrade shorter peptides more rapidly) and store reconstituted vials at 4 °C for up to 4 weeks. Because MOTS-c is derived from a mitochondrial gene, its natural sequence is highly conserved — verify the supplier is using the correct human MOTS-c sequence rather than a murine variant, which differs slightly in amino acid composition and may have different potency in human tissue contexts.

MOTS-c occupies a unique niche among metabolic peptides because its mechanism begins within the mitochondrion itself — it is literally encoded in the organelle whose dysfunction it remedies. Compared to Humanin (another mitochondria-derived peptide discovered by the same Cohen group), MOTS-c has stronger metabolic effects — particularly on insulin sensitivity and glucose disposal — while Humanin's advantages lie more in neuroprotection and cardioprotection. The two MDPs are often discussed as a complementary pair, targeting overlapping but distinct aspects of mitochondrial-mediated healthspan. Against GLP-1 receptor agonists such as semaglutide, MOTS-c operates through an entirely different mechanism that is weight-loss agnostic — its insulin-sensitizing effects are not primarily driven by appetite suppression or caloric restriction but by direct enhancement of mitochondrial metabolic efficiency. MOTS-c users often report improved body composition without significant weight loss, reflecting a shift in substrate utilization toward fat oxidation rather than a reduction in total energy intake. For individuals with metabolic dysfunction who also wish to preserve or improve physical performance, MOTS-c's exercise-mimetic profile and enhancement of exercise capacity makes it a compelling choice compared to the purely appetite-suppressive GLP-1 agonists.